Trial Profile
A pilot phase II study of OSI-774 (Tarceva™; OSI Pharmaceuticals) [erlotinib] prior to cystectomy for patients with muscle invasive bladder cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2005
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 28 Jul 2005 New trial record.